Drugs / DepoCyte
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | DepoCyte | — | 2001-07-11 | europa.eu ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00388531 | Mar 2006 → Mar 2011 | acute lymphoblastic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00198978 | Jan 2003 → Jun 2011 | adult acute lymphoblastic leukemia | Goethe University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01458730 Background | May 2007 → Oct 2010 | central nervous system non-hodgkin lymphoma | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DepoCyte | “The objective of the study is 1. To investigate the efficacy and safety of a high-dose methotrexate-based induction polychemotherapy regimen combined with Rituximab and...” NCT01458730 ↗ |